A Single Immunization With Modified Vaccinia Virus Ankara-Based Influenza Virus H7 Vaccine Affords Protection in the Influenza A(H7N9) Pneumonia Ferret Model

Kreijtz, Joost H. C. M.; Wiersma, Lidewij; Gruyter, Heidi L.M. De; Trierum, Stella E. Vogelzang-van; Amerongen, Geert van; Stittelaar, Koert J.; Fouchier, Ron A. M.; Osterhaus, Albert D. M. E.; Sutter, Gerd; Rimmelzwaan, Guus F.

doi:10.1093/infdis/jiu528

Cited by 29 publications

(21 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New production platforms with the capacity to produce large quantities of vaccines in a short period is in urgent need. The first H7N9 viral vector vaccine based on modified vaccinia virus Ankara (MVA) was proved to be immunogenic, even after a single immunization [15]. In this study, we demonstrate a feasible vaccine strategy that overcomes the poor immunogenicity of egg-derived or recombinant protein antigens.…”

Section: Discussionmentioning

confidence: 91%

“…Those individuals who have high levels of virus-specific CD8 + T cells develop less severe illness [19]. The HAd-H7HA vaccine induces strong CD4 and CD8 T cell responses which are crucial in conferring protective immunity [14, 15]. Therefore, the HAd-H7HA vaccine developed in this study could potentially serve as a pre-pandemic or pandemic vaccine against A(H7N9) influenza virus infections.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A highly immunogenic vaccine against A/H7N9 influenza virus

Cao

Liepkalns

Hassan

et al. 2016

Vaccine

View full text Add to dashboard Cite

Since the first case of human infection in March 2013, continued reports of H7N9 cases highlight a potential pandemic threat. Highly immunogenic vaccines to this virus are urgently needed to protect vulnerable populations who lack protective immunity. In this study, an egg- and adjuvant-independent adenoviral vector-based, hemagglutinin H7 subtype influenza vaccine (HAd-H7HA) demonstrated enhanced cell-mediated immunity as well as serum antibody responses in a mouse model. Most importantly, this vaccine provided complete protection against homologous A/(H7N9) viral challenge suggesting its potential utility as a pandemic vaccine.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

A highly immunogenic vaccine against A/H7N9 influenza virus

Cao

Liepkalns

Hassan

et al. 2016

Vaccine

View full text Add to dashboard Cite

show abstract

“…Another type of vaccine is the cell-based H7N1 split influenza virion, which was shown to confer protection in the mouse and ferret challenge models [37]. More recently, protection against H7N9 viruses has been reported using viral vector vaccines [38,39]. …”

Section: Discussionmentioning

confidence: 99%

Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets

Liu

Massare

Pearce

et al. 2015

Vaccine

View full text Add to dashboard Cite

In March 2013, diagnosis of the first reported case of human infection with a novel avian-origin influenza A(H7N9) virus occurred in eastern China. Most human cases have resulted in severe respiratory illness and, in some instances, death. Currently there are no licensed vaccines against H7N9 virus, which continues to cause sporadic human infections. Recombinant virus-like particles (VLPs) have been previously shown to be safe and effective vaccines for influenza. In this study, we evaluated the immunogenicity and protective efficacy of a H7N9 VLP vaccine in the ferret challenge model. Purified recombinant H7N9 VLPs morphologically resembled influenza virions and elicited high-titer serum hemagglutination inhibition (HI) and neutralizing antibodies specific for A/Anhui/1/2013 (H7N9) virus. H7N9 VLP-immunized ferrets subsequently challenged with homologous virus displayed reductions in fever, weight loss, and virus shedding compared to these parameters in unimmunized control ferrets. H7N9 VLP was also effective in protecting against lung and tracheal infection. The addition of either ISCOMATRIX or Matrix-M1 adjuvant improved immunogenicity and protection of the VLP vaccine against H7N9 virus. These results provide support for the development of a safe and effective human VLP vaccine with potent adjuvants against avian influenza H7N9 virus with pandemic potential.

show abstract

“…However, there are currently no approved human vaccines for H7N9 viruses. Experimental vaccines have been developed for H7N9 and other H7 subtype viruses including live attenuated H7N7 and H7N3 vaccines [24–26], inactivated H7N7 vaccine [27], cell-based H7N1 split virus vaccine [28], and viral vector vaccines [29,30]. Recently, immunization with a live attenuated H7N9 influenza experimental vaccine protected mice against lethal challenge [31].…”

Section: Introductionmentioning

confidence: 99%

“…Recently, immunization with a live attenuated H7N9 influenza experimental vaccine protected mice against lethal challenge [31]. Furthermore, immunization with modified vaccinia virus vector resulted in protection against H7N9 virus challenge in a ferret model [32]. Recombinant H7N9 protein vaccines based on expression of HA in heterologous expression systems have been also reported (see below).…”

Section: Introductionmentioning

confidence: 99%

Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza virus

Li¹,

Pushko

Tretyakova

2015

J Vaccines Vaccin

View full text Add to dashboard Cite

Cases of H7N9 human infection were caused by a novel, avian-origin H7N9 influenza A virus that emerged in eastern China in 2013. Clusters of human disease were identified in many cities in China, with mortality rates approaching 30%. Pandemic concerns were raised, as historically, influenza pandemics were caused by introduction of novel influenza A viruses into immunologically naïve human population. Currently, there are no approved human vaccines for H7N9 viruses. Recombinant protein vaccine approaches have advantages in safety and manufacturing. In this review, we focused on evaluation of the expression of recombinant hemagglutinin (rHA) proteins as candidate vaccines for H7N9 influenza, with the emphasis on the role of oligomeric and particulate structures in immunogenicity and protection. Challenges in preparation of broadly protective influenza vaccines are discussed, and examples of broadly protective vaccines are presented including rHA stem epitope vaccines, as well as recently introduced experimental multi-HA VLP vaccines.

show abstract

A Single Immunization With Modified Vaccinia Virus Ankara-Based Influenza Virus H7 Vaccine Affords Protection in the Influenza A(H7N9) Pneumonia Ferret Model

Cited by 29 publications

References 46 publications

A highly immunogenic vaccine against A/H7N9 influenza virus

A highly immunogenic vaccine against A/H7N9 influenza virus

Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets

Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza virus

Contact Info

Product

Resources

About